Why your employer, not your insurer, usually decides
This is the fact that makes the rest of the page make sense, and most coverage pages never state it.
Large employers commonly self-fund their health plans: the employer pays the claims from its own money and sets the benefit design, while an insurer administers the plan and puts its logo on the card. Under that arrangement, the insurer is not the party deciding whether weight-loss medication is a covered category — your employer is.
Weight-loss drug coverage is one of the most common things to include or exclude at that level, which is exactly why you can compare notes with someone carrying an identical-looking card and get a different answer. Neither of you is wrong, and neither of you made a mistake on the paperwork.
The practical consequence: searching for whether “Aetna covers Wegovy” cannot answer your question.An insurer's general policy is a starting point, not a verdict on your plan. Ten minutes on the phone with your own plan beats any amount of reading about the insurer.
How each payer type actually behaves
| Payer type | Weight-management coverage | Who really decides |
|---|---|---|
| Self-funded employer plan | Included or excluded as a category — varies enormously | Your employer |
| Fully-insured commercial plan | Depends on the plan purchased | Employer choice among insurer products |
| ACA marketplace plan | Not federally required; varies by plan and state | The specific plan you bought |
| Medicare Part D | Excluded for weight loss by statute | Federal law — not appealable on that basis |
| Medicaid | State by state via the preferred drug list | Your state Medicaid program |
| TRICARE / VA | Federal programs with their own formularies and criteria | The program, not an insurer |
Deeper: how coverage and appeals work · TRICARE · VA · Medicare
Published insurer postures
For orientation only — each insurer publishes a general position, and your plan can differ from it in either direction.
| Payer | Typically covered | Typically excluded |
|---|---|---|
| UnitedHealthcare (Commercial) | Ozempic for type 2 diabetes — typically considered for coverage on most UHC commercial PDLs with prior authorization and step therapy; verify with your specific plan and current formulary.; Mounjaro for type 2 diabetes — typically considered for coverage with prior authorization documenting T2D diagnosis and often a metformin trial; verify with your specific plan and current formulary. | Off-label weight-loss use of Ozempic, Mounjaro, or Rybelsus — generally not covered; T2D documentation is typically required; Compounded semaglutide and tirzepatide — almost universally excluded from UHC commercial formularies as non-FDA-approved |
| Anthem Blue Cross Blue Shield | Ozempic (semaglutide) for T2D — generally on formulary with PA requiring diabetes documentation; tier and step therapy vary by plan, verify with your specific plan and current formulary; Mounjaro (tirzepatide) for T2D — typically covered with PA, often step therapy through metformin first; verify with your specific plan and current formulary | Wegovy, Zepbound, Saxenda for weight loss under self-funded employer plans that have elected to exclude anti-obesity medications (common across large ASO employer groups); Off-label use of T2D GLP-1s (Ozempic, Mounjaro, Rybelsus) for weight loss without a T2D diagnosis — denied as not medically necessary |
| Aetna (Commercial) | Ozempic for T2D when diabetes documentation criteria are met — verify tier and PA requirements with your specific plan and current formulary; Mounjaro for T2D under standard diabetes PA criteria — verify with your specific plan and current formulary | Weight-loss GLP-1s under self-funded employer plans that have carved out anti-obesity medications; Off-label use of T2D GLP-1s (Ozempic, Mounjaro) prescribed solely for weight loss without a T2D diagnosis |
| Kaiser Permanente | Ozempic (semaglutide) for documented T2D, subject to regional formulary tier and step therapy — verify with your specific plan and current formulary; Mounjaro (tirzepatide) for documented T2D, often with prior authorization — verify with your specific plan and current formulary | Weight-loss GLP-1s (Wegovy, Zepbound, Saxenda) under Kaiser plans whose employer/benefit design excludes obesity pharmacotherapy; Off-label weight-loss prescribing of T2D-labeled GLP-1s (Ozempic, Mounjaro, Rybelsus) without a T2D diagnosis |
| Medicare Part D | Ozempic (semaglutide) when prescribed for type 2 diabetes with documentation — coverage, tier, and PA requirements vary by plan; verify with your specific plan and current year formulary; Mounjaro (tirzepatide) when prescribed for type 2 diabetes with documentation — coverage and PA requirements vary by plan; verify with your specific plan and current year formulary | Any GLP-1 prescribed solely for weight loss or chronic weight management — statutorily excluded under SSA §1860D-2(e)(2)(A); Wegovy prescribed for obesity without the cardiovascular risk reduction indication |
| Medicare Advantage (Part C with Part D / MA-PD) | Ozempic (semaglutide) when prescribed for type 2 diabetes with documented diagnosis — coverage and tier vary by plan formulary; verify with your specific plan and current formulary; Mounjaro (tirzepatide) when prescribed for type 2 diabetes with documented diagnosis — coverage varies by plan; verify with your specific plan and current formulary | Any GLP-1 prescribed solely for weight loss or chronic weight management — statutorily excluded under SSA §1860D-2(e)(2)(A); Wegovy prescribed for weight management without the cardiovascular indication |
| Medicaid (general — varies by state) | Ozempic for T2D when on the state Preferred Drug List and clinical criteria are met — verify with your specific state Medicaid formulary and current PDL; Mounjaro for T2D when on the state PDL with prior authorization — verify with your specific state Medicaid formulary and current PDL | Weight-loss GLP-1s (Wegovy, Zepbound, Saxenda) in the majority of state Medicaid programs that have elected the §1927(d)(2) exclusion; Off-label use of T2D-indicated GLP-1s (Ozempic, Mounjaro) for weight loss without a documented T2D diagnosis |
| Federal Employee Program BCBS (FEP) | Ozempic (semaglutide) for type 2 diabetes with diabetes documentation — verify with your specific plan and current formulary; Mounjaro (tirzepatide) for type 2 diabetes with diabetes documentation — verify with your specific plan and current formulary | Off-label weight-loss use of T2D-only GLP-1s (e.g., Ozempic, Mounjaro) without a diabetes diagnosis; Compounded semaglutide/tirzepatide from 503A/503B facilities (generally not covered by commercial plans including FEP) |
| Self-Funded Employer Plans (ASO) | Ozempic for T2D — typically covered with PA requiring A1c documentation; verify with your specific plan and current formulary; Mounjaro for T2D — typically covered with PA and often step therapy through metformin; verify with your specific plan and current formulary | Anti-obesity medications under employers that have adopted a categorical AOM exclusion (common among cost-sensitive mid-market employers); Compounded semaglutide/tirzepatide — virtually universally excluded by PBMs as non-FDA-approved |
| ACA Marketplace Plans | Ozempic when prescribed for type 2 diabetes with documented diagnosis — coverage and tier vary by issuer; verify with your specific plan and current formulary; Mounjaro when prescribed for type 2 diabetes with documented diagnosis — typically subject to prior authorization; verify with your specific plan and current formulary | GLP-1s prescribed solely for weight loss on plans that have adopted an anti-obesity drug exclusion (the majority of marketplace plans); Off-label use of T2D-indicated GLP-1s (Ozempic, Mounjaro, Rybelsus) for weight loss without a diabetes diagnosis |
| Cigna (Commercial) | Ozempic (semaglutide) for type 2 diabetes may be considered for coverage; verify with your specific plan and current formulary; Mounjaro (tirzepatide) for type 2 diabetes may be considered for coverage; verify with your specific plan and current formulary | Compounded semaglutide and tirzepatide — not FDA-approved as finished products and routinely excluded from Cigna/Express Scripts commercial benefits; Anti-obesity medications under employer groups that have elected an explicit weight-loss drug carve-out |
| Humana | Ozempic for type 2 diabetes with documented diagnosis and prior auth — may be considered for coverage; verify with your specific plan and current formulary; Mounjaro for type 2 diabetes with A1C documentation and typical step therapy — may be considered for coverage; verify with your specific plan and current formulary | Wegovy, Zepbound, and Saxenda when prescribed solely for weight loss under Humana Medicare Advantage Part D or stand-alone Part D plans (federal statutory exclusion); Off-label use of T2D GLP-1s (Ozempic, Mounjaro) for weight loss without a documented diabetes diagnosis |
How to check your own plan in ten minutes
1. "Is this drug on my formulary, and at what tier?"
Tier drives your copay. Ask for the specific product name — Wegovy and Ozempic are different products even though both are semaglutide.
2. "Does it require prior authorization, and what exactly do you require?"
Ask them to send the written clinical criteria. You cannot meet a standard you have not read, and you are entitled to it.
3. "Does my plan include weight-loss medication at all, or is it excluded?"
The question people skip. It decides whether an appeal can ever work, and it takes one sentence to ask.
Bonus: "What is my 30-day retail copay versus 90-day mail order?"
Frequently a meaningful difference on a medication you will take indefinitely, and almost nobody asks.
The route that works when weight-loss is excluded
If your benefit excludes weight-loss medication, no clinical argument changes that — but the exclusion is written around weight loss as a use, and two of these drugs carry a second, non-weight indication:
- Wegovy — cardiovascular risk reduction in adults with established heart disease plus overweight or obesity.
- Zepbound — moderate-to-severe obstructive sleep apnea in adults with obesity.
Because neither is a weight-loss use, coverage can apply through them where the exclusion would otherwise block everything. Whether it applies depends entirely on your documented diagnosis — that is a question for your prescriber, not an angle to adopt, and we are not suggesting anyone claim a condition they do not have.
Denial versus exclusion — read the letter first
Criteria denial — worth fighting
The plan covers the drug but says you did not meet requirements. Missing baseline weight, undocumented prior therapy, a diagnosis code that never reached the form. Usually paperwork, frequently reversed.
Benefit exclusion — change paths
The category is not covered. That is what was purchased, or what statute requires. No evidence overturns it — spend the effort on a different indication or a cash route instead.
If it is a criteria denial: how to appeal · formulary exceptions
If the answer stays no
Cash routes are cheaper than the list prices imply. Zepbound self-pay starts at $299/mo (2.5 mg)[zepbound], Wegovy runs about $349/month at maintenance, and the oral Wegovy pill starts around $149. Patient assistance can supply medication at no cost to uninsured, income-qualified patients — the most commonly skipped route, because it requires an application.
Every cash route in order · cheapest GLP-1 · patient assistance
Coverage is plan-specific and changes. This describes how the system works as of 2026-07-20 — it is information, not coverage advice. Your plan documents govern your situation.